Discover Log In Sign Up
VRTX
Vertex Pharmaceuticals Incorporated
+291%
+14.6% per year

Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.

Country US
Exchange NASDAQ
Industry Biotechnology
Sector Healthcare
Market Cap $116.71B
CEO Dr. Reshma Kewalramani FASN, M.D.

Vertex Pharmaceuticals is a biotechnology company that creates medicines for people with cystic fibrosis, a genetic condition that affects the lungs and digestive system. They have developed several important drugs, like SYMDEKO and KALYDECO, that help patients manage their symptoms. In addition to cystic fibrosis, Vertex is also working on treatments for other serious health issues, such as diabetes and kidney diseases. The company sells its products mainly through special pharmacies and hospitals in the U.S. and around the world.

Core Products

๐Ÿ’Š
ORKAMBI For specific CF mutations
๐Ÿ’Š
KALYDECO CF treatment for mutations
๐Ÿ’Š
TRIKAFTA Treats CF for age 6+
๐Ÿ’Š
SYMDEKO/SYMKEVI Cystic fibrosis therapy

Business Type

B2B Business to Business

Competitive Advantages

๐Ÿฅ
Specialized Market Focus The company's focus on cystic fibrosis and related conditions allows for deep expertise and strong relationships within a niche market.
๐Ÿค
Strategic Collaborations Vertex's partnerships with leading biotech and pharmaceutical companies enhance its research capabilities and market access.
โญ
Established Brand Reputation Years of successful product launches and clinical advancements have built Vertex a strong and reputable brand in the biotech sector.
๐Ÿ’‰
Strong Pipeline of Therapies Vertex has a robust pipeline of innovative therapies targeting specific genetic mutations and diseases, providing a sustainable competitive edge.
๐Ÿ”’
Intellectual Property Protection Vertex holds extensive patents for its therapies, providing legal protection against competition and ensuring market exclusivity.

Key Business Risks

๐Ÿงช
Pipeline Risk Failure of clinical trials for key drug candidates could significantly affect future revenue.
โš–๏ธ
Regulatory Risk Changes in regulations or approval processes can delay or prevent product launches.
๐Ÿค
Collaboration Risk Potential issues with strategic partnerships may hinder development and commercialization efforts.
๐Ÿ
Market Competition Intense competition from other biotech firms could impact market share and pricing.
๐Ÿ”‘
Dependency on Key Products Heavy reliance on a few products for revenue makes the company vulnerable to market changes.

Meeting Expectations

0 /0

Higher values indicate better execution and credibility

Recent Results

Takeaways

Vertex Pharmaceuticals exhibits strong business attractiveness due to its innovative product pipeline and established market position in cystic fibrosis therapies, coupled with solid financial health and effective management. However, ongoing competition and regulatory risks present challenges that temper its overall robustness.

Historical data shows an impressive CAGR compared with the USA stock market average, reflecting a strong market position.

Yearly Return 10Y annualized return is very good at 14.6% per year
Earnings Expectations VRTX has met or exceeded earnings expectations in all recent quarters (0/0)

Continue with...

Home Screener Search Profile

During the beta period, we're currently displaying stocks from the S&P 500 index only. More stocks will be added soon.

Loading...